Login to Your Account

Zafgen shares swell on beloranib efficacy in 'crucial first step' to resolve clinical hold

By Marie Powers
News Editor

Wednesday, January 20, 2016

Shares of Zafgen Inc. more than doubled early and trading was heavy after the company reported positive efficacy results from the bestPWS ZAF-311 study of beloranib in patients with Prader-Willi syndrome.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription